目的 觀察小兒肺熱咳喘顆粒治療兒童支原體肺炎的療效和安全性。方法 將2017年3月-2018年4月丹東市中心醫(yī)院收治的240例兒童支原體肺炎患兒隨機(jī)分為對照組和試驗(yàn)組，每組各120例。對照組口服小兒肺熱咳喘顆粒模擬劑，開水沖服，1~2歲1袋/次，3次/d；3~5歲1袋/次，4次/d。試驗(yàn)組給予小兒肺熱咳喘顆粒，用法用量同對照組。兩組療程均為14 d。比較兩組患兒的臨床痊愈天數(shù)、完全退熱時間、咳嗽、咯痰緩解時間、中醫(yī)證候療效。結(jié)果 用藥后，試驗(yàn)組臨床痊愈中位時間為4.00 d，對照組為7.00 d；試驗(yàn)組完全退熱中位時間為3.00 d，對照組為4.00 d；試驗(yàn)組咳嗽緩解中位時間為6.00 d，對照組為7.00 d；試驗(yàn)組咯痰緩解中位時間為4.00 d，對照組為5.00 d，試驗(yàn)組明顯短于對照組，兩組比較差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，試驗(yàn)組患者中醫(yī)證候有效率為92.24%，對照組為82.20%，兩組比較，差異有統(tǒng)計學(xué)意義（P<0.05）。兩組不良事件發(fā)生率比較，差異無統(tǒng)計學(xué)意義。結(jié)論 小兒肺熱咳喘顆粒治療兒童支原體肺炎在縮短病程、改善患兒癥狀方面療效確切，且用藥安全性較好，無不良反應(yīng)發(fā)生，值得在兒科推廣。

Objective To observe the efficacy and safety of Xiaoer Feire Kechuan Granules in treatment of mycoplasma pneumonia in children. Methods A total of 240 children with mycoplasma pneumonia admitted to Dandong Central Hospital from March 2017 to April 2018 were randomly divided into control group and experimental group, with 120 cases in each group. Patients in the control group were po administered with Xiaoer Feire Kechuan Granules simulant for children, 1 bag/time for 1-2 years old, 3 times daily; 3-5 years old 1 bag/time, 4 times daily. Patients in the treatment group were po administered with Xiaoer Feire Kechuan Granules, and the usage and dosage of Xiaoer Feire Kechuan Granules in experimental group were the same as those in control group. The treatment course for both groups was 14 d. Clinical recovery days, complete fever reduction time, cough and phlegm relief time, and TCM syndrome efficacy were compared between the two groups. Results After treatment, the median clinical recovery time was 4.00 d in the experimental group and 7.00 d in the control group. The median time of complete fever reduction was 3.00 d in the experimental group and 4.00 d in the control group. The median time of remission was 6.00 d in the experimental group and 7.00 d in the control group. The median time of sputum remission was 4.00 d in the experimental group and 5.00 d in the control group, which was significantly shorter than that in the control group, and the difference between the two groups was statistically significant (P<0.05). After treatment, the effective rate of TCM syndrome was 92.24% in the experimental group and 82.20% in the control group, and the difference between the two groups was statistically significant (P<0.05). There was no significant difference in the incidence of adverse events between the two groups. Conclusion Xiaoer Feire Kechuan Granules has a definite effect on shortening the course of the disease and improving the symptoms of children with mycoplasma pneumonia, with good drug safety and no adverse reactions, which is worth promoting in pediatrics.

R974